Ferris Robert L, Baloch Zubair, Bernet Victor, Chen Amy, Fahey Thomas J, Ganly Ian, Hodak Steven P, Kebebew Electron, Patel Kepal N, Shaha Ashok, Steward David L, Tufano Ralph P, Wiseman Sam M, Carty Sally E
1 Division of Head and Neck Surgery, Department of Otolaryngology, University of Pittsburgh Cancer Institute , Pittsburgh, Pennsylvania.
2 Department of Pathology, University of Pennsylvania Medical Center , Philadelphia, Pennsylvania.
Thyroid. 2015 Jul;25(7):760-8. doi: 10.1089/thy.2014.0502. Epub 2015 Jun 24.
Recent advances in research on thyroid carcinogenesis have yielded applications of diagnostic molecular biomarkers and profiling panels in the management of thyroid nodules. The specific utility of these novel, clinically available molecular tests is becoming widely appreciated, especially in perioperative decision making by the surgeon regarding the need for surgery and the extent of initial resection.
A task force was convened by the Surgical Affairs Committee of the American Thyroid Association and was charged with writing this article.
RESULTS/CONCLUSIONS: This review covers the clinical scenarios by cytologic category for which the thyroid surgeon may find molecular profiling results useful, particularly for cases with indeterminate fine-needle aspiration cytology. Distinct strengths of each ancillary test are highlighted to convey the current status of this evolving field, which has already demonstrated the potential to streamline decision making and reduce unnecessary surgery, with the accompanying benefits. However, the performance of any diagnostic test, that is, its positive predictive value and negative predictive value, are exquisitely influenced by the prevalence of cancer in that cytologic category, which is known to vary widely at different medical centers. Thus, it is crucial for the clinician to know the prevalence of malignancy within each indeterminate cytologic category, at one's own institution. Without this information, the performance of the diagnostic tests discussed below may vary substantially.
甲状腺癌发生机制的最新研究进展已将诊断性分子生物标志物和分析组合应用于甲状腺结节的管理。这些新型的、临床可用的分子检测的具体效用正得到广泛认可,尤其是在外科医生进行围手术期决策时,涉及手术必要性及初始切除范围。
美国甲状腺协会外科事务委员会召集了一个特别工作组负责撰写本文。
结果/结论:本综述涵盖了甲状腺外科医生可能发现分子分析结果有用的按细胞学分类的临床情况,特别是对于细针穿刺细胞学结果不确定的病例。强调了每种辅助检测的独特优势,以传达这一不断发展领域的当前状况,该领域已显示出简化决策并减少不必要手术的潜力及附带益处。然而,任何诊断检测的性能,即其阳性预测值和阴性预测值,都受到该细胞学分类中癌症患病率的极大影响,已知不同医疗中心的患病率差异很大。因此,临床医生了解自己所在机构每个不确定细胞学分类中的恶性肿瘤患病率至关重要。没有这些信息,下面讨论的诊断检测的性能可能会有很大差异。